Anakinra ineffective for reducing symptoms of chronic fatigue

Anakinra ineffective for reducing symptoms of chronic fatigue

(HealthDay)—The anti-inflammatory biologic drug anakinra (Kineret) does not reduce fatigue severity in women with chronic fatigue syndrome, according to a study published online March 7 in the Annals of Internal Medicine.

To test anakinra's potential as a treatment, Megan E. Roerink, M.D., of the Radboud University Medical Centre in Nijmegen, Netherlands, and colleagues randomly assigned 25 women with syndrome to receive daily 100-mg injections of the drug. Another 25 women received a .

After one month, the researchers saw no meaningful difference between the two groups in fatigue severity. Other symptoms—including pain, distress, and physical and social functioning—were not appreciably different, either.

"Peripheral interleukin-1 inhibition using anakinra for four weeks does not result in a clinically significant reduction in fatigue severity in women with and severe fatigue," the authors write.


Explore further

Fatigue occurs in 50 percent with chronic plaque psoriasis

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: Anakinra ineffective for reducing symptoms of chronic fatigue (2017, March 8) retrieved 19 January 2021 from https://medicalxpress.com/news/2017-03-anakinra-ineffective-symptoms-chronic-fatigue.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments